Annual EBIT
-$118.95 M
+$20.97 M+14.99%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual earnings before interest & taxes is -$118.95 million, with the most recent change of +$20.97 million (+14.99%) on December 31, 2023.
- During the last 3 years, KPTI annual EBIT has risen by +$49.87 million (+29.54%).
- KPTI annual EBIT is now -1053.65% below its all-time high of -$10.31 million, reached on December 31, 2011.
Performance
KPTI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$20.66 M
-$53.47 M-162.97%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly earnings before interest & taxes is -$20.66 million, with the most recent change of -$53.47 million (-162.97%) on September 30, 2024.
- Over the past year, KPTI quarterly EBIT has dropped by -$53.47 million (-162.97%).
- KPTI quarterly EBIT is now -144.39% below its all-time high of $46.54 million, reached on December 31, 2021.
Performance
KPTI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$54.76 M
+$7.76 M+12.42%
September 30, 2024
Summary
- As of February 8, 2025, KPTI TTM earnings before interest & taxes is -$54.76 million, with the most recent change of +$7.76 million (+12.42%) on September 30, 2024.
- Over the past year, KPTI TTM EBIT has increased by +$7.76 million (+12.42%).
- KPTI TTM EBIT is now -1406.38% below its all-time high of -$3.63 million, reached on September 30, 2012.
Performance
KPTI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
KPTI EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.0% | -163.0% | +12.4% |
| 3 y3 years | +29.5% | +52.7% | +69.7% |
| 5 y5 years | +32.4% | +46.0% | +70.2% |
KPTI EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.7% | +15.0% | -144.4% | +51.5% | at high | +60.9% |
| 5 y | 5-year | -21.7% | +35.3% | -144.4% | +60.4% | at high | +70.2% |
| alltime | all time | -1053.7% | +35.3% | -144.4% | +67.3% | -1406.4% | +73.6% |
Karyopharm Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$20.66 M(-163.0%) | -$54.76 M(-12.4%) |
| Jun 2024 | - | $32.81 M(-204.5%) | -$62.52 M(-48.8%) |
| Mar 2024 | - | -$31.41 M(-11.5%) | -$122.05 M(+2.6%) |
| Dec 2023 | -$118.95 M(-15.0%) | -$35.50 M(+24.9%) | -$118.95 M(+2.5%) |
| Sep 2023 | - | -$28.42 M(+6.4%) | -$116.00 M(-1.5%) |
| Jun 2023 | - | -$26.72 M(-5.6%) | -$117.75 M(-11.9%) |
| Mar 2023 | - | -$28.31 M(-13.0%) | -$133.66 M(-4.5%) |
| Dec 2022 | -$139.93 M(+43.1%) | -$32.55 M(+7.9%) | -$139.93 M(+130.0%) |
| Sep 2022 | - | -$30.16 M(-29.2%) | -$60.84 M(-18.2%) |
| Jun 2022 | - | -$42.63 M(+23.3%) | -$74.37 M(-7.3%) |
| Mar 2022 | - | -$34.59 M(-174.3%) | -$80.19 M(-18.0%) |
| Dec 2021 | -$97.77 M(-42.1%) | $46.54 M(-206.5%) | -$97.77 M(-45.9%) |
| Sep 2021 | - | -$43.70 M(-9.8%) | -$180.60 M(-1.6%) |
| Jun 2021 | - | -$48.45 M(-7.1%) | -$183.55 M(+5.1%) |
| Mar 2021 | - | -$52.17 M(+43.8%) | -$174.64 M(+3.4%) |
| Dec 2020 | -$168.82 M(-8.2%) | -$36.29 M(-22.2%) | -$168.82 M(-3.4%) |
| Sep 2020 | - | -$46.65 M(+18.0%) | -$174.72 M(+5.0%) |
| Jun 2020 | - | -$39.53 M(-14.7%) | -$166.32 M(-0.5%) |
| Mar 2020 | - | -$46.36 M(+9.9%) | -$167.11 M(-9.1%) |
| Dec 2019 | -$183.90 M(+4.6%) | -$42.18 M(+10.3%) | -$183.90 M(-6.8%) |
| Sep 2019 | - | -$38.25 M(-5.1%) | -$197.43 M(-4.7%) |
| Jun 2019 | - | -$40.32 M(-36.2%) | -$207.24 M(+3.3%) |
| Mar 2019 | - | -$63.15 M(+13.4%) | -$200.59 M(+14.0%) |
| Dec 2018 | -$175.89 M | -$55.70 M(+15.9%) | -$175.89 M(+11.3%) |
| Sep 2018 | - | -$48.07 M(+42.8%) | -$158.02 M(+12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$33.67 M(-12.4%) | -$141.01 M(+2.9%) |
| Mar 2018 | - | -$38.45 M(+1.6%) | -$137.09 M(+6.3%) |
| Dec 2017 | -$128.92 M(+17.8%) | -$37.84 M(+21.8%) | -$128.92 M(+10.2%) |
| Sep 2017 | - | -$31.05 M(+4.4%) | -$116.96 M(+4.8%) |
| Jun 2017 | - | -$29.75 M(-1.7%) | -$111.64 M(-0.6%) |
| Mar 2017 | - | -$30.28 M(+17.0%) | -$112.37 M(+2.7%) |
| Dec 2016 | -$109.44 M(-8.1%) | -$25.87 M(+0.5%) | -$109.44 M(-3.0%) |
| Sep 2016 | - | -$25.74 M(-15.5%) | -$112.87 M(-4.1%) |
| Jun 2016 | - | -$30.48 M(+11.4%) | -$117.74 M(-2.1%) |
| Mar 2016 | - | -$27.35 M(-6.7%) | -$120.28 M(+1.0%) |
| Dec 2015 | -$119.08 M(+57.1%) | -$29.30 M(-4.3%) | -$119.08 M(+3.0%) |
| Sep 2015 | - | -$30.61 M(-7.3%) | -$115.65 M(+10.4%) |
| Jun 2015 | - | -$33.01 M(+26.2%) | -$104.78 M(+18.8%) |
| Mar 2015 | - | -$26.15 M(+1.1%) | -$88.22 M(+16.4%) |
| Dec 2014 | -$75.78 M(+123.2%) | -$25.87 M(+31.0%) | -$75.78 M(+22.1%) |
| Sep 2014 | - | -$19.74 M(+20.0%) | -$62.05 M(+20.2%) |
| Jun 2014 | - | -$16.45 M(+20.0%) | -$51.63 M(+22.8%) |
| Mar 2014 | - | -$13.71 M(+12.9%) | -$42.05 M(+23.9%) |
| Dec 2013 | -$33.95 M(+113.7%) | -$12.14 M(+30.3%) | -$33.95 M(+30.4%) |
| Sep 2013 | - | -$9.32 M(+35.7%) | -$26.04 M(+27.9%) |
| Jun 2013 | - | -$6.87 M(+22.4%) | -$20.35 M(+50.9%) |
| Mar 2013 | - | -$5.61 M(+32.4%) | -$13.48 M(+71.3%) |
| Dec 2012 | -$15.89 M(+54.1%) | -$4.24 M(+16.6%) | -$7.87 M(+116.6%) |
| Sep 2012 | - | -$3.63 M | -$3.63 M |
| Dec 2011 | -$10.31 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual EBIT year-on-year change?
- What is Karyopharm Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly EBIT year-on-year change?
- What is Karyopharm Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM EBIT year-on-year change?
What is Karyopharm Therapeutics annual earnings before interest & taxes?
The current annual EBIT of KPTI is -$118.95 M
What is the all time high annual EBIT for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual earnings before interest & taxes is -$10.31 M
What is Karyopharm Therapeutics annual EBIT year-on-year change?
Over the past year, KPTI annual earnings before interest & taxes has changed by +$20.97 M (+14.99%)
What is Karyopharm Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of KPTI is -$20.66 M
What is the all time high quarterly EBIT for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly earnings before interest & taxes is $46.54 M
What is Karyopharm Therapeutics quarterly EBIT year-on-year change?
Over the past year, KPTI quarterly earnings before interest & taxes has changed by -$53.47 M (-162.97%)
What is Karyopharm Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of KPTI is -$54.76 M
What is the all time high TTM EBIT for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM earnings before interest & taxes is -$3.63 M
What is Karyopharm Therapeutics TTM EBIT year-on-year change?
Over the past year, KPTI TTM earnings before interest & taxes has changed by +$7.76 M (+12.42%)